Table 1.
Antidiabetic agents in hospitalized patients with type 2 diabetes and COVID-19 [53].
| Hospitalized moderate disease | Hospitalized severe disease (ICU patients) | |
|---|---|---|
| Recommended | ✓ Insulin | ✓ Insulin |
| ✓ DPP4 inhibitor | ✓ DPP4 inhibitor | |
| ✓ GLP-1 analogues | ||
| ✓ Metformin | ||
| Not recommended | ✓ Thiazolidinedione | ✓ Thiazolidinedione |
| ✓ SGLT2 inhibitors | ✓ SGLT2 inhibitors | |
| ✓ Sulfonylurea | ||
| Use with caution | ✓ Sulfonylurea | ✓ Metformin |
| ✓ α-Glucosidase inhibitors | ✓ α-Glucosidase inhibitors | |
| ✓ GLP-1 analogues |
[DPP4: Dipeptidyl peptidase-4, SGLT2: Sodium glucose transporter 2, GLP-1: Glucagon-like peptide-1].